[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiology":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,83,108,131,167,193,218,251,277],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644486","applying-the-intention-action-framework-to-specialty-referrals-100644486",false,"NCT07671976","Applying the Intention-Action Framework to Specialty Referrals","Reducing Low-Value Care: Applying the Intention-Action Framework to Specialty Referrals","Inclusion Criteria:\n\n* UCLA Health physicians who have made at least one specialty referral to cardiology, pulmonology, or gastroenterology for patients in UCLA Health primary care registry during July-December 2025\n\nExclusion Criteria:\n\n* Physicians who are no longer actively practicing at UCLA Health as of July 1, 2026","ALL","18 Years",{"count":19,"type":20},1600,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective randomized controlled trial evaluating an EHR-embedded behavioral intervention intended to reduce low-value specialty referrals in cardiology, pulmonology, and gastroenterology. The intervention is designed to (1) strengthen physicians' intentions to avoid low-value specialty referrals at the point of encounter by presenting criteria for high-value referrals and informing physicians that referral decisions may be reviewed and (2) support follow-through on these intentions by modifying the referral process through structured checklist prompts embedded within the referral workflow.\n\nThe primary hypothesis is that physicians exposed to the intervention will demonstrate lower rates of low-value cardiology, pulmonology, and gastroenterology referrals compared with physicians exposed to the arm where the order composer allows physicians to place referrals with minimal decision support.",[26,27,28],"Cardiology","Gastroenterology","Pulmonology",[30,31,32,33,26,28,27],"Low-value referral","Behavioral science","Physician decision-making","Quality improvement","NOT_YET_RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":20},"2026-07-01",{"date":42,"type":20},"2027-01-31",{"name":44,"class":45},"University of California, Los Angeles","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":46},"100638712","pulse---patient-understanding-and-learning-through-structured-education---effectiveness-and-implementation-of-patient-education-videos-in-a-new-pediatric-cardiology-clinic-a-stepped-wedge-cluster-randomized-trial-100638712","NCT07594041","PULSE - Patient Understanding and Learning Through Structured Education - Effectiveness and Implementation of Patient Education Videos in a New Pediatric Cardiology Clinic: A Stepped Wedge Cluster Randomized Trial","PULSE","Inclusion Criteria:\n\nPediatric patients (ages 0-18 years) presenting for outpatient pediatric cardiology evaluation Caregiver present and able to complete surveys Referral reason matches available video topic (during intervention periods)\n\nExclusion Criteria:\n\nEmergency or urgent consultations Caregiver unable to read\u002Funderstand English or Spanish Patient\u002Ffamily opts out of study participation",{"count":55,"type":20},300,[23],"This study is looking at whether short educational videos shown during pediatric cardiology visits can help families better understand their child's condition while also making clinic visits run more efficiently. Families coming to a pediatric cardiology clinic may watch short videos related to why they are there (for example: chest pain, heart murmurs, fainting, sports clearance, or Kawasaki disease). The videos are meant to explain common heart-related conditions and answer questions before the doctor comes into the room.\n\nResearchers want to see if this:\n\n* helps parents and patients learn more,\n* improves satisfaction with the visit,\n* helps families feel more involved in decisions,\n* and reduces the amount of time doctors spend repeating the same explanations.\n\nHow the study works:\n\nOne clinic site in San Antonio, TX will start using the videos at different times. Researchers will compare clinic visits before and after the videos are introduced.\n\nWho is included:\n\nChildren being seen in pediatric cardiology clinics and their caregivers. Pregnant women referred for fetal heart evaluations may also be included.\n\nWhat information is collected:\n\nClinic timing information (such as wait times and doctor visit length), Satisfaction surveys, Optional knowledge questionnaires, Basic medical record information needed for the study.\n\nRisk level: The study is considered \"minimal risk.\" Patients are still getting normal medical care. No drugs, devices, or experimental treatments are being tested.\n\nPrivacy protections: Data will be stored on secure hospital systems. Researchers plan to remove identifying information when analyzing results. Medical record numbers are only temporarily used to connect survey data with clinic data.\n\nWhy the study matters:\n\nThe clinic hopes the videos can make visits less stressful, improve understanding for families, and help doctors spend more time on personalized care instead of repeating the same explanations over and over. It may also help clinics work more efficiently and reduce delays.",[26,59,60,61,62,63],"Pediatric Cardiac Surgery","Education","Patient Education","Shared Decision-making","Outpatient Clinics, Hospital",[65,66,67,68,69,70,71,72,73],"patient education","videos","outpatient","pediatric","cardiology","pediatric cardiology","shared decision making","outpatient clinic","implementation science","2026-05-12",{"date":76,"type":38},"2026-05-18",{"date":78,"type":20},"2026-05",{"date":80,"type":20},"2027-12",{"name":82,"class":45},"Driscoll Children's Hospital",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100569433","safe-and-explainable-ai-100569433","NCT06694181","Safe and Explainable AI","SAFE AND EXPLAINABLE AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT","Inclusion Criteria:\n\nCardiology 18 years of age and older, admitted to any of the Penn Medicine hospitals from 2017 to the present. Sepsis 18 years of age at the time of presentation to an emergency department or admission to any Penn Medicine hospital from July 1, 2017, onward will be eligible as this represents the population at risk for acquiring sepsis Oncology 18 years of age and older with a diagnosis of invasive breast cancer (Stage 1-4) in the Penn Cancer registry\n\nExclusion Criteria All prediction models will exclude patients under the age of 18 from their patient data sets.\n\nCardiology Patients whose primary admission diagnosis was cardiac arrest Sepsis Those with pre-existing limitations on life-sustaining therapy will be excluded because their eligibility for sepsis definitions, care received, and outcomes, may be significantly and variably affected by pre-existing limitations on care. Oncology There are no other exclusions.",{"count":91,"type":20},300000,"OBSERVATIONAL","While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowledge effectively, making AI recommendations explainable to clinicians, and establishing safety guarantees.",[95,26,96,97],"Artifical Inteligence","Breast Cancer","Sepsis","RECRUITING","2026-02-23",{"date":101,"type":38},"2026-02-25",{"date":103,"type":38},"2025-11-29",{"date":105,"type":20},"2028-11",{"name":107,"class":45},"Abramson Cancer Center at Penn Medicine",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":46},"100603716","dual-anti-platelet-optimized-stent-for-high-bleeding-risk-patient-100603716","NCT07140133","Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient","DIOHR","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Male or female patient requiring a coronary angioplasty procedure according to European recommendations,\n* Patients undergoing revascularization with HT-supreme stents\n* Patient at high risk of bleeding according to ARC HBR definition (9).\n* Patient affiliated to or benefiting from a social security scheme\n* Patient who does not object to research\n\nExclusion Criteria:\n\n* Estimated lifespan \\\u003C1 year,\n* Allergy and any other contraindication to aspirin and\u002For clopidogrel listed in the summary of product characteristics,\n* Allergy to iodinated contrast media\n* Adults under legal protection (guardianship, curatorship or safeguard of justice).\n* Persons deprived of their liberty by judicial or administrative decision,\n* Patient in a period of relative exclusion from another research protocol,",{"count":116,"type":20},1200,"High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events, particularly in HBR patients, compared with longer DAPT. European guidelines therefore authorize one-month DAPT in HBR patients presenting even an acute coronary syndrome.\n\nThe HT Supreme Drug Coated Coronary Stent System (HT Supreme DES) is designed to promote reendothelialization as quickly as possible. That's why the stent is called \"HT\" Supreme, with \"HT\" standing for \"Healing Targeted\", enabling a DAPT of just 1 month in all-comers HBR patients.\n\nThanks to these features, the investigators aim to demonstrate ischemic and hemorrhagic complication rates lower than those found in the literature with other stent.",[119,26,120,121],"High Bleeding Risk Patients","Stent Implantation","DAPT(Dual Antiplatelet Therapy)","2025-08-21",{"date":124,"type":38},"2025-08-24",{"date":126,"type":20},"2025-09",{"date":128,"type":20},"2027-09",{"name":130,"class":45},"University Hospital, Grenoble",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":152,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100593588","high-sensitivity-troponin-i-in-addition-to-guideline-based-care-in-ems-100593588","NCT07008391","High-Sensitivity Troponin I in Addition to Guideline-Based Care in EMS","High-Sensitivity Troponin I in Addition to Guideline-Based Care in Emergency Medical Service - an Open Randomized Controlled Trial","TIGER","Inclusion Criteria:\n\n* Chestpain \u002F discomfort and\u002For\n* Clinical suspicion of myocardial infarction by the prehospital personeel\n\nExclusion Criteria:\n\n* Patients suffering from a trauma and conveyed to the trauma level 1 hospital.\n* Missing valid social security number\n* Not beeing able to give informed consent\n* Not a primary assignment",true,{"count":141,"type":20},1419,[23],"The TIGER study is a study investigating the utlility of a point-of-care blood analyse of Troponin I to help identify patients with heart attacks in the prehospital emergency care. The study is conducted within the ambulance services of Region Stockholm and compares standard medical care with and without the addition of this quick test.\n\nChest pain is one of the most common reasons for ambulance dispatch, but currently only about one-third of heart attacks are detected before arriving at the hospital-mainly through ECG. The remaining two-thirds are not identified until after further testing at the emergency department. The TIGER study aims to improve early diagnosis by using a high-sensitivity, point-of-care Troponin I test already in the prehospital phase.\n\nThe study is a randomized controlled trial, where participants are randomly assigned to one of two groups. One group receives standard emergency care along with the rapid Troponin I test in the ambulance. The other group receives standard care without the test. The goal is to evaluate whether the use of Troponin I testing leads to faster and more accurate identification of heart attacks, ultimately improving patient outcomes.\n\nIn total, about 1,419 adult patients with chest pain or suspected heart attack will participate. The primary outcome being measured is the time from first medical contact to PCI (balloon angioplasty). Secondary outcomes include time spent in different parts of care, hospital length of stay, the occurrence of serious events (such as heart attack, stroke, or death), and the diagnostic accuracy of the test.\n\nThe study has been approved by the Swedish Ethical Review Authority and includes safety monitoring through an interim analysis after the first 150 patients. Test results from the Troponin I analysis are clearly marked as part of the research study and should be interpreted by the responsible physician alongside other clinical findings.",[145,146,26,147,148,149,150,151],"Emergency Medical Services","Nursing Care","Myocardial Infarction","Myocardial Infarction or Chest Pain","Myocardial Infarction, Acute","Emergencies","Ambulance",[151,153,154,155,156,157],"Prehospital emergency nurse","Sweden","Point-of-care","troponin","high sensitive troponin","2025-06-27",{"date":160,"type":38},"2025-07-02",{"date":162,"type":38},"2025-06-25",{"date":164,"type":20},"2026-12-30",{"name":166,"class":45},"Karolinska Institutet",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":46},"100587966","large-language-models-to-improve-the-quality-of-care-of-cardiology-patients-100587966","NCT06935253","Large Language Models To Improve the Quality of Care of Cardiology Patients","Towards Bridging Generalists to Subspecialists With Large Language Models","Inclusion Criteria:\n\n* Board certified or board eligible Cardiologist.\n\nExclusion Criteria:\n\n* Not currently practicing clinically",{"count":175,"type":20},12,[23],"This study evaluates the impact of large language models (LLMs) versus traditional decision support tools on clinical decision-making in cardiology. General cardiologists will be randomized to manage real patient cases from a cardiovascular genetic cardiomyopathy clinic, with or without AI assistance. Each case will be assessed by two cardiologists, and their responses will be graded by blinded subspecialty experts using a standardized evaluation rubric.",[179,180,181,26],"Hypertrophic Cardiomyopathy (HCM)","Cardiomyopathy","Genetic Disease",[183,26],"Large language models","2025-05-13",{"date":186,"type":38},"2025-05-15",{"date":188,"type":38},"2025-01-10",{"date":190,"type":20},"2025-12",{"name":192,"class":45},"Stanford University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":199,"targetDuration":201,"studyType":92,"phases":4,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":46},"100585126","utility-of-gene-test-analysis-for-diagnosis-prognosis-and-treatment-of-patients-with-genetic-arrhythmic-heart-disease-the-arrhythmic-gene-heart-100585126","NCT06898307","Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART","Inclusion Criteria:\n\n* Patients evaluated at the Cardiogenetic Center of the University of Ferrara in Ferrara, Italy.\n* Having a proven cardiogenetic disease\n\nExclusion Criteria:\n\n* Refuse to provide informed consents\n* Patients not having a cardiogenic disease",{"count":200,"type":20},200,"10 Years","The goal of this observational study is to enroll all patients evaluated at the specialized Cardiogenetic Center within the Cardiology Department of the University of Ferrara, Italy. The primary aim of the registry is to collect comprehensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. By systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry seeks to enhance our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes. This registry will facilitate long-term follow-up of enrolled patients to assess the natural history of arrhythmogenic disorders and the effectiveness of various therapeutic interventions. Additionally, it aims to identify potential risk factors associated with adverse outcomes, such as sudden cardiac death or major arrhythmic events.",[181,204,205,206,26],"Cardiac Disease","Cardiac Arrhythmias","Genetic Disorder",[208],"Cardiogenetic","2025-03-26",{"date":211,"type":38},"2025-03-27",{"date":213,"type":38},"2017-11-01",{"date":215,"type":20},"2035-11-01",{"name":217,"class":45},"University Hospital of Ferrara",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":46},"100579636","phase-2-efficacy-and-safety-of-spc1001-in-patients-with-essential-hypertension-100579636","NCT06826872","Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","A Multicenter, Randomized, Double-Blind, Parallel, Phase 2(2b) Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","Inclusion Criteria:\n\n* Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.\n\nExclusion Criteria:\n\n* Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.","19 Years","75 Years",{"count":228,"type":20},252,[230],"PHASE2","\\- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.\n\n\\- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.\n\n\\- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.\n\n\\- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration.\n\nScreening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.",[233,234,26],"Hypertension, Essential","Cardiovascular Diseases",[236,237,238,239,240],"blood pressure","Low-dose combination therapy","candesartan","amlodipine","indapamide","2025-02-10",{"date":243,"type":38},"2025-02-14",{"date":245,"type":38},"2024-06-12",{"date":247,"type":20},"2025-12-30",{"name":249,"class":250},"Shin Poong Pharmaceutical Co. Ltd.","INDUSTRY",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":226,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100467665","screening-of-coronary-artery-disease-100467665","NCT05369728","Screening Of CoRonary ArTEry diSease","Medico-economic Evaluation of a Strategy With Coronary CT as First Line (CCTA) Compared With the Strategy With Functional Test as First Line, in Patients at Intermediate Risk of Developing Stable Coronary Disease.","SOCRATES","Inclusion Criteria:\n\n* Patients aged 18 to 75 years\n* Symptomatic patient in whom CAD cannot be excluded by clinical evaluation alone : patient with a pre-test or \"intermediate\" clinical probability indicating imaging test according to European recommendations\n* Patient affiliated to the social security system or beneficiary of such a system\n* Written informed consent\n\nExclusion Criteria:\n\n* Pre-test probability \"low\" \\\u003C 5% or 5-15% without additive pejorative factors\n* Clinical probability of \"high\" CAD, defined by symptoms typical of low exercise levels not responding to medical therapies\n* Known history of CAD\n* Severe impairment of left ventricular ejection fraction \\\u003C 40%.\n* Known chronic renal failure not on dialysis (GFR \\\u003C30 ml \u002F min \u002F1.73 m²)\n* Patient considered unfit for the study according to the investigator's judgement and in particular the impossibility of performing an anatomical and\u002For functional test of ischemia of the coronary disease\n* Patient in a period of exclusion for another study\n* Persons referred to in articles L1121-5 to L1121-8 of the public health code\n* Patient participating in another interventional research",{"count":260,"type":20},800,[23],"This study is a randomized trial with the objective of comparing the cost-effectiveness of the 2 recommended strategies: CCTA vs functional tests, allowing the evaluation of the quality of life of these patients in relation to the health resources used.\n\nIn symptomatic patients with an intermediate probability of having stable CAD, i.e., whose pretest or clinical probability does not allow the elimination of the disease, and in patients without anginal symptoms for low levels of exercise who do not respond to medical therapy, in France, the diagnostic care pathways have become mature enough to set up a pragmatic prospective randomized trial with the objective of comparing the cost-effectiveness of the 2 recommended strategies: CCTA vs.\n\nProbabilistic medico-economic reasoning makes it possible to establish this two-way hypothesis more easily than in clinical research without the need to impose the superiority of one of the strategies.",[26,264],"Coronary Artery Disease",[266,267,268],"Medico-economic study","Coronary CT scanner","Cardiac functionel test","2022-05-05",{"date":271,"type":38},"2022-05-11",{"date":273,"type":20},"2022-05",{"date":275,"type":20},"2026-10",{"name":130,"class":45},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100268807","france-pci-registry--national-observatory-of-interventional-cardiology-100268807","NCT02778724","France PCI Registry : National Observatory of Interventional Cardiology","Inclusion Criteria:\n\n* Age =\\>18 years at enrollment\n* Patient who have had a coronary angiogram or angioplasty\n\nExclusion Criteria:\n\n* Patient who didn't want to participated",{"count":284,"type":20},40000,"Rigorous clinical practice assessment is a key factor to improve patient's care and prognosis in interventional cardiology (IC). A multicentric IC observational study (CRAC), fully integrated to usual coronary activity report software, started in Centre Val de Loire (CVL) region in 2014.\n\nCRAC observatory was conduced on five IC CathLab of CVL region. Quality of collected data is regularly evaluated and allowed building an exhaustive, and reliable database. This solution could easily be developed in other French regions.",[287,26,288,289,290,291],"Interventional","Angioplasty","Coronary","STEMI","Database","2022-03-29",{"date":294,"type":38},"2022-04-07",{"date":296,"type":4},"2014-01",{"date":298,"type":20},"2030-12",{"name":300,"class":45},"Club Régional des Angioplasticiens de la région Centre",15]